Résumé
OBJECTIVE: To examine trends, characteristics, and oncologic outcomes of sentinel lymph node biopsy for early endometrial cancer. METHODS: This observational study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program by examining 83,139 women with endometrial cancer who underwent primary hysterectomy with nodal evaluation for T1 disease from 2003 to 2018. Primary outcome measures were the temporal trends in utilization of sentinel lymph node biopsy and patient characteristics associated with sentinel lymph node biopsy use, assessed by multivariable binary logistic regression models. Secondary outcome measure was endometrial cancer-specific mortality associated with sentinel lymph node biopsy, assessed by propensity score inverse probability of treatment weighting. RESULTS: The utilization of sentinel lymph node biopsy increased from 0.2 to 29.7% from 2005 to 2018 (P<.001). The uptake was higher for women with endometrioid (0.3-31.6% between 2005 and 2018) compared with nonendometrioid (0.6-21.0% between 2006 and 2018) histologic subtypes (both P<.001). In a multivariable analysis, more recent year surgery, endometrioid histology, well-differentiated tumors, T1a disease, and smaller tumor size were independently associated with sentinel lymph node biopsy use (P<.05). Performance of sentinel lymph node biopsy was not associated with increased endometrial cancer-specific mortality compared with lymphadenectomy for endometrioid tumors (subdistribution hazard ratio [HR] 0.96, 95% CI 0.82-1.13) or nonendometrioid tumors (subdistribution HR 0.85, 95% CI 0.69-1.04). For low-risk endometrial cancer, the increase in sentinel lymph node biopsy resulted in a 15.3 percentagepoint (1.4-fold) increase in surgical nodal evaluation by 2018 (expected vs observed rates, 37.8 vs 53.1%). CONCLUSION: The landscape of surgical nodal evaluation is shifting from lymphadenectomy to sentinel lymph node biopsy for early endometrial cancer in the United States, with no indication of a negative effect on cancerspecific survival.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 809-820 |
| Nombre de pages | 12 |
| Journal | Obstetrics and Gynecology |
| Volume | 139 |
| Numéro de publication | 5 |
| DOI | |
| Statut de publication | Published - mai 1 2022 |
Financement
Supported by the Ensign Endowment for Gynecologic Cancer Research (K.M.). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Koji Matsuo reports receiving travel expense for investigator meeting attendance expense from VBL Therapeutics. Lynda D. Roman reports receiving funding from Quantgene, Inc. and AXDEV. Jason D. Wright received royalties from UpToDate for writing/review of chapters related to cervical dysplasia, human papillomavirus, and cervical cancer. He served as a consultant for Clovis Oncology and participated in their advisory board (March 2019). He performed medicolegal review of malpractice cases related to delayed diagnosis of gynecologic cancer and intraoperative complications during gynecologic surgery. He is currently serving on the SGO Board of Directors (no monetary compensation), from 2019 to 2022. He conducted epidemiologic research trials examining patterns of care for ovarian, uterine, and cervical cancer for Merck. Lastly, he also has performed analysis of and provided education on clinical trials data for Otsuka Pharmacovigilance. The other authors did not report any potential conflicts of interest.
| Bailleurs de fonds | Numéro du bailleur de fonds |
|---|---|
| AXDEV | |
| Ensign Endowment for Gynecologic Cancer Research | |
| Quantgene, Inc. |
ASJC Scopus Subject Areas
- Obstetrics and Gynaecology
ODD de l’ONU
Cette action contribue à la réalisation des objectifs de développement durable suivants
